Qiagen NV (QGEN) Stock AnalysisQGENQiagen NV

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight. It operates in the Healthcare sector.

Qiagen NV (QGEN) is a good buy right now, with a current price of $45.38 and a forward P/E ratio of 13.53, indicating potential undervaluation compared to future earnings. The recent appointment of a new CEO, Jonathan Pratt, is expected to drive strategic growth, and analysts have raised their price targets, with Barclays now at $55, suggesting a 21% upside from the current price. However, a risk to consider is the significant selling by hedge funds, which increased by 286.76% over the last quarter, indicating potential bearish sentiment among institutional investors.

10 analysts cover QGEN: 3 rate it Buy, 7 Hold and 0 Sell. The average price target is 50.57.